文献速递间质性肺疾病肺结节与肺癌

布格替尼诱导自身免疫性肺泡蛋白沉积症一例并文献复习

[Autoimmune pulmonary alveolar proteinosis induced by brigatinib: a case report and literature review].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2026-01-01

本研究为病例系列研究,纳入1例布格替尼诱导的自身免疫性PAP病例及文献检索的4例TKI诱导PAP病例,共5例。中位发病时间5个月,4例血清KL-6升高,3例抗GM-CSF抗体升高,5例均经BALF细胞学和/或肺组织病理确诊。治疗包括未治疗、全肺灌洗和雾化吸入GM-CSF,转归不一。

要点

  • TKI治疗期间出现间质性肺炎且停药和激素无效时,应警惕PAP并行BALF和/或肺活检。
  • 血清KL-6和抗GM-CSF抗体升高可辅助提示TKI诱导的自身免疫性PAP。
  • 雾化吸入GM-CSF或全肺灌洗可能是TKI诱导自身免疫性PAP的有效治疗选择。

核心结论

  • TKI可诱导罕见的自身免疫性PAP,诊断需结合影像、BALF细胞学和/或肺组织病理。
  • 雾化吸入GM-CSF或全肺灌洗可能是TKI诱导自身免疫性PAP的有效治疗手段。

研究设计与样本

  • 本研究为病例系列研究,纳入南京大学医学院附属鼓楼医院呼吸与危重症医学科1例布格替尼诱导的自身免疫性PAP患者。
  • 检索万方数据库、中国知网和PubMed截至2025年10月31日的文献,补充纳入4例TKI诱导PAP患者,共5例。

主要发现

  • 5例患者中男性1例、女性4例,使用TKI后诱发PAP的中位发病时间为5个月(范围1.3~21个月)。
  • 原发病包括肺癌2例、血液肿瘤3例;3例使用伊马替尼(其中1例先后更换为尼洛替尼、达沙替尼),奥希替尼和布格替尼各1例。
  • 4例血清KL-6水平显著升高;3例血清抗GM-CSF抗体水平升高,其中1例BALF中GM-CSF水平上升。
  • 胸部影像学显示双肺磨玻璃影2例、双肺斑片状渗出1例、典型「铺路石征」2例;5例均经BALF细胞学和/或肺组织病理学确诊PAP。
  • 治疗上2例未治疗、2例全肺灌洗、1例雾化吸入GM-CSF;转归为1例死于呼吸衰竭、1例更换TKI后死于原发病进展、2例症状改善病情稳定、1例预后良好。

关键数值与推荐

  • 使用TKI后诱发PAP的中位发病时间为5个月(范围1.3~21个月)。
  • 4例患者血清KL-6水平显著升高,3例血清抗GM-CSF抗体水平升高。
  • 5例患者均经BALF细胞学和/或肺组织病理学明确诊断PAP。

临床怎么用

  • TKI治疗期间出现间质性肺炎改变,经停药和激素治疗无效时,应仔细分析胸部影像学特征。
  • 需进行支气管肺泡灌洗和/或支气管镜肺活检以明确PAP诊断。
  • 确诊TKI诱导的自身免疫性PAP后,可考虑雾化吸入GM-CSF或全肺灌洗治疗。

局限性

  • 本研究为病例系列研究,样本量小(共5例),证据级别有限。
  • 文献检索截至2025年10月31日,可能遗漏未发表或未收录的病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical features, diagnostic and therapeutic considerations, and outcomes of pulmonary alveolar proteinosis (PAP) induced by tyrosine kinase inhibitor (TKI), aiming to enhance clinicians' understanding of this rare form of interstitial lung disease associated with TKI. Methods: This was a case series study. One case of autoimmune PAP induced by brigatinib from the Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, was collected. A literature search of the Wanfang Database, China National Knowledge Infrastructure (CNKI), and PubMed up to October 31, 2025, identified an additional four cases of TKI-induced PAP. A total of five cases were included. The baseline clinical characteristics, imaging findings, pathological results, treatments, and clinical outcomes of these five patients were summarized and analyzed. Results: Among the five patients, one was male and four were female. The median time from TKIs initiation to PAP onset was 5 months (range: 1.3-21 months). Underlying diseases included lung cancer (2 cases) and hematologic malignancies (3 cases). Three patients were treated with imatinib (one later switched to nilotinib and then dasatinib), while one patient each received osimertinib and brigatinib. Serum KL-6 levels were significantly elevated in four patients. Anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody levels were elevated in the serum of three patients, with one also showing increased GM-CSF levels in bronchoalveolar lavage fluid (BALF). Chest imaging revealed bilateral ground-glass opacities in two cases, bilateral patchy infiltrates in one case, and the typical "crazy-paving pattern" in two cases. The diagnosis of PAP was confirmed in all five patients via BALF cytology and/or lung tissue histopathology. Treatment for PAP consisted of no specific therapy in two patients, whole lung lavage (WLL) in two, and inhaled GM-CSF in one. Regarding clinical outcomes, one patient died of respiratory failure, one died of primary disease progression after switching TKI, two showed symptomatic improvement with stable disease, and one had a favorable prognosis. Conclusions: Autoimmune PAP is a rare pulmonary complication associated with TKI. When interstitial pneumonia occurs during TKI administration and does not respond to drug withdrawal and corticosteroid treatment, careful analysis of chest imaging features, along with bronchoalveolar lavage and/or bronchoscopic lung biopsy, is necessary for a definitive diagnosis. This case series and literature review suggest that nebulized GM-CSF or whole lung lavage (WLL) may be effective treatment options for TKI-induced autoimmune PAP. 目的: 探讨酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)诱发肺泡蛋白沉积症(pulmonary alveolar proteinosis,PAP)的临床特征、诊疗要点及转归,以期提高临床医师对TKI导致该种罕见间质性肺病的认识。 方法: 本研究为病例系列研究,收集来自南京大学医学院附属鼓楼医院呼吸与危重症医学科的1例自身免疫性PAP患者,以及对万方数据库、中国知网和PubMed数据库中2025年10月31日前报道的所有PAP进行文献检索,最终纳入4例TKI诱发PAP患者,总结分析5例患者的基线临床特征、影像学资料、病理结果、治疗和临床转归。 结果: 5例患者中男性1例,女性4例。使用TKI后诱发PAP的中位发病时间为5个月(1.3~21个月)。原发病包括肺癌2例,血液肿瘤3例。其中3例使用伊马替尼(其中1例先后更换为尼洛替尼、达沙替尼),使用奥希替尼和布格替尼患者各1例。4例患者血清涎液化糖链抗原-6(Krebs von den Lungen-6,KL-6)水平显著升高。3例患者血清抗粒细胞-巨噬细胞集落刺激因子(granulocyte macrophage-colony stimulating factor,GM-CSF)抗体水平升高,其中1例支气管肺泡灌洗液(bronchoalveolar lavage fluid,BALF)中GM-CSF水平上升。胸部影像学上,双肺磨玻璃影2例,双肺斑片状渗出1例,典型“铺路石征”2例。5例患者均经肺泡灌洗液细胞学和(或)肺组织病理学明确诊断PAP。治疗上,2例患者PAP未治疗,2例给予全肺灌洗(whole lung lavage,WLL),1例雾化吸入GM-CSF。PAP转归:1例因呼吸衰竭死亡,1例更换TKI药物后因原发病进展死亡,2例症状改善,病情稳定,另有1例预后良好。 结论: TKI治疗肿瘤疾病中,可诱导自身免疫性PAP发生,但相当罕见。当TKI诱发肺部出现间质性肺炎改变,经停药和激素治疗无效时,需要仔细分析胸部影像学特征,并进行支气管肺泡灌洗和(或)支气管镜肺活检明确诊断。本例及文献回顾提示,雾化吸入GM-CSF或WLL可能是治疗TKI诱导的自身免疫性PAP的有效手段。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Hou SX, Li W, Chen M, et al. [Autoimmune pulmonary alveolar proteinosis induced by brigatinib: a case report and literature review]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42236457. doi:10.3760/cma.j.cn112147-20251224-00816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。